Eris Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
- Paid Up Capital ₹ 13.61 Cr
- Company Age 18 Year, 27 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1,812.32 Cr
- Satisfied Charges ₹ 815.00 Cr
- Revenue Growth 8.30%
- Profit Growth -4.60%
- Ebitda 4.36%
- Net Worth 15.81%
- Total Assets 29.45%
About Eris Lifesciences
Eris Lifesciences Limited (ELL) is a leading Public Limited Indian Non-Government Company incorporated in India on 25 January 2007 and has a history of 18 years. Its registered office is in Ahmedabad, Gujarat, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 540596 and on the National Stock Exchange(NSE) under ERIS.
The Corporate was formerly known as Eris Lifesciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 13.61 Cr.
The company currently has active open charges totaling ₹1,812.32 Cr. The company has closed loans amounting to ₹815.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Eris Lifesciences Limited India are Mr Shah as CFO and Milind Talegaonkar as Company Secretary. Rajeev Dalal, Kaushal Shah, Amit Bakshi, and Five other members serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
Industry
What products or services does Eris Lifesciences Limited offer?
Eris Lifesciences Limited offers a wide range of products and services, including Health Conditions, Bone, Joint & Muscle Care, Women Care, Women Care Supplements, Healthcare Devices, BP Monitors, Mental Wellness, Popular Category, Mind Care, Specialty Supplements.
Who are the key members and board of directors at Eris Lifesciences?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mr Shah  | CFO | Current | |
| Amit Bakshi | Managing Director | 27-Jan-2007 | Current |
| Milind Talegaonkar | Company Secretary | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajeev Dalal | Director | 19-Dec-2020 | Current |
| Kaushal Shah | Director | 27-Jan-2007 | Current |
| Inderjeet Negi | Whole-Time Director | 25-Jan-2007 | Current |
Kalpana Unadkat  | Director | 05-Jan-2021 | Current |
| Prashant Gupta | Director | 30-Apr-2018 | Current |
| Sujesh Vasudevan | Director | 25-Jul-2022 | Current |
Financial Performance of Eris Lifesciences.
Eris Lifesciences Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.3% increase. The company also saw a slight decrease in profitability, with a 4.6% decrease in profit. The company's net worth Soared by an impressive increase of 15.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eris Lifesciences?
In 2022, Eris Lifesciences had a promoter holding of 52.66% and a public holding of 47.33%. The company had 5 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eris Bionxt Private LimitedKaushal Shah and Inderjeet Negi are mutual person
Aprica Healthcare LimitedKaushal Shah is a mutual person
Eris M. J. Biopharm Private LimitedKaushal Shah, Amit Bakshi and 1 more are mutual person
Tvs Credit Services LimitedKalpana Unadkat is a mutual person
Hetero Labs LimitedSujesh Vasudevan is a mutual person
Swiss Parenterals LimitedKaushal Shah and Krishnakumar Vaidyanathan are mutual person
Charges (Loans)
₹1,812.32 Cr
₹815.00 Cr
Charges Breakdown by Lending Institutions
- Citi Bank N.A. : 525.82 Cr
- Hdfc Bank Limited : 512.00 Cr
- Others : 437.50 Cr
- Axis Bank Limited : 337.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Feb 2024 | Others | ₹437.50 Cr | Open |
| 27 Dec 2023 | Hdfc Bank Limited | ₹212.00 Cr | Open |
| 21 Dec 2023 | Citi Bank N.A. | ₹280.00 Cr | Open |
| 21 Aug 2023 | Citi Bank N.A. | ₹120.82 Cr | Open |
| 26 Jul 2023 | Axis Bank Limited | ₹337.00 Cr | Open |
How Many Employees Work at Eris Lifesciences?
Eris Lifesciences has a workforce of 3305 employees as of Aug 14, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eris Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eris Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
